Copyright 2009 by Northwestern University School of Law
Northwestern University Law Review Colloquy

Vol. 103

KEEPING THE LABEL OUT OF THE CASE
Mark Herrmann* and Pearson Bownas**

INTRODUCTION
The FDA approves prescription drugs and medical devices for only the
specific uses indicated in the product labeling that the manufacturer submits
in the approval process. A physician may determine, however, that a use
not indicated in the FDA-approved labeling—an ―off-label‖ use—would
benefit a patient. This Article argues that in medical malpractice cases involving an off-label use, the product‘s label should not be admitted as evidence of either the standard of care or the physician‘s alleged breach of that
standard.
I.

OFF-LABEL USE EXPLAINED

A. The FDA Approves Drugs and Devices for Only Specified “Intended
Uses”
Prescription drugs and certain medical devices cannot be sold and
marketed in the United States unless the Food and Drug Administration
(―FDA‖) approves them.1 The FDA approval regimes for drugs and medical devices require manufacturers to submit proposed labeling.2 This labeling must include, among other things, indications of the product‘s intended
use, such as the conditions it treats, the appropriate patient population, and
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1
See, e.g., 21 U.S.C. §§ 355 (drugs) (link), 360e (devices) (link) (2006). The FDA drug and device
approval regimes are discussed in detail in James M. Beck & Elizabeth D. Azari, FDA, Off-Label Use,
and Informed Consent: Debunking Myths and Misconceptions, 53 FOOD & DRUG L.J. 71, 72–76 (1998).
2
E.g., 21 U.S.C. §§ 355(b)(1) (drugs), 360e(c)(1)(F) (devices); 21 C.F.R. § 314.50(c)(2)(i) (2008)
(drugs) (link).
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administration and dosage information.3 When the FDA approves a drug or
device for sale and marketing, it does so only with respect to the indicated
uses.4
The FDA-approved label may also include ―contraindications‖ and
―warnings and precautions.‖ A ―contraindication‖ is a ―situation[] in which
the drug should not be used because the risk of use . . . clearly outweighs
any possible therapeutic benefit.‖5 ―Warnings and precautions‖ are descriptions of ―clinically significant adverse reactions . . . , other potential safety
hazards . . . , limitations in use imposed by them . . . , and steps that should
be taken if they occur,‖ as well as any other ―information regarding any
special care to be exercised by the practitioner for safe and effective use of
the drug . . . .‖6
The analysis in this Article is limited to off-label uses that are not contraindicated, warned against, or identified by a precaution. In a medical
malpractice action involving a use that is contraindicated, for example, the
FDA-approved label should be admissible because the FDA has analyzed
that very use and concluded that the associated risk is unacceptable.7 By
contrast, in an action involving a use as to which the FDA-approved label is
silent, the FDA has not reached the same conclusion. The FDA may simply
not have considered the use being litigated, and the label listing the FDAapproved uses is therefore irrelevant to determining whether the standard of
care has been met.
B. Off-Label Use Is Widespread
Although the FDA approves drugs and medical devices for only the
uses indicated in the product labeling, drugs and devices may have other,
off-label uses that are beneficial.8 For example, physicians may use a product to treat a disease other than the one (or ones) the drug or device was ap-

3

E.g., 21 C.F.R. §§ 201.56(d)(1) (link), 201.57(c)(2)–(3) (drugs) (link), 801.109 (devices) (link)
(2008).
4
See, e.g., 21 U.S.C. §§ 355(d) (drugs), 360e(d)(1)(A)(ii), 360e(d)(2)(A)–(B) (devices). Cf. 21
C.F.R. § 201.57(c)(2)(ii) (―If there is a common belief that [a] drug may be effective for a certain use or
if there is a common use of the drug for a condition, but the preponderance of evidence related to the use
or condition shows that the drug is ineffective or that the therapeutic benefits . . . do not generally outweigh its risks, FDA may require [a statement] that there is a lack of evidence that the drug is effective
or safe for that use or condition.‖).
5
21 C.F.R. § 201.57(c)(5).
6
Id. § 201.57(c)(6)(i)–(ii).
7
For the same reason, in a medical malpractice case involving an ―on-label‖ use, the prescribing
physician should be allowed to offer the label as evidence that the FDA has considered that use and determined it to be safe and effective. See James R. Bird, Comment, Package Inserts for Prescription
Drugs as Evidence in Medical Malpractice Suits, 44 U. CHI. L. REV. 398, 445–46 (1977). This Article
does not address what, if any, evidence plaintiffs may offer to try to offset that showing.
8
See, e.g., MayoClinic.com, Off-Label Drugs and Medical Devices: Get the Facts,
http://www.mayoclinic.com/health/off-label/DI00088 (last visited Apr. 2, 2009) (link).
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proved to treat.9 Or, physicians may prescribe a drug or device for a person
outside the approved patient population.10 Physicians may also administer
drugs by different routes, or in different doses or frequency, than approved
by the FDA.11
Off-label use of drugs and medical devices is common. Between twenty-five and sixty percent of all drug prescriptions written may be for offlabel uses.12 For some conditions, the percentage is even higher. One report estimates that sixty-five percent of all cancer drug use is off-label.13
Other studies estimate that seventy percent of kidney dialysis patients use
their equipment off-label,14 and that more than eighty percent of AIDS patients are receiving at least one off-label drug treatment.15
II. THE FDA-APPROVED DRUG OR DEVICE LABEL SHOULD NOT BE
ADMITTED IN AN OFF-LABEL USE CASE
Virtually all medical treatments carry some degree of risk. 16 When a
physician treats a patient with an off-label use and the patient is injured in
9

Id.
Id.
11
Id.; Lars Noah, Constraints on the Off-Label Uses of Prescription Drug Products, 16 J. PROD. &
TOXICS LIAB. 139, 140–41 (1994).
12
Beck & Azari, supra note 1, at 80; Noah, supra note 11, at 139.
13
U.S. GEN. ACCOUNTING OFFICE, PROGRAM EVALUATION & METHODOLOGY DIV. NO. 91-14,
OFF-LABEL DRUGS: REIMBURSEMENT POLICIES CONSTRAIN PHYSICIANS IN THEIR CHOICE OF CANCER
THERAPIES 13 (1991) [hereinafter GAO REPORT], available at http://archive.gao.gov/d18t9/144933.pdf
(link). See also, e.g., P. G. Casali, The Off-Label Use of Drugs in Oncology: A Position Paper by the
European Society for Medical Oncology (ESMO), 18 ANNALS ONCOLOGY 1923, 1923 (2007) (internal
citations omitted) (―The off-label use of drugs in oncology has been estimated to reach 50%, or even
more.‖) (link).
14
FDA and Dialyzer Makers Spar Over Device Reuse, FOOD & DRUG LETTER, Apr. 8, 1994, at 3.
15
Carol L. Brosgart et al., Off-Label Drug Use in Human Immunodeficiency Virus Disease, 12 J.
ACQUIRED IMMUNE DEFICIENCY SYNDROMES & HUMAN RETROVIROLOGY 56, 57–58 (1996). Other
conditions with standard off-label use treatments have included heart and circulatory disease, osteoporosis, spinal injuries requiring fusion surgery, and incontinence. Beck & Azari, supra note 1, at 80 & n.80.
Because historically drugs were rarely tested on children, the FDA rarely had the data necessary to approve drugs for use on children. Thus, as many as eighty percent of prescriptions written for children
were for off-label uses. See, e.g., Lauren Hammer Breslow, Note, The Best Pharmaceuticals for Children Act of 2002: The Rise of the Voluntary Incentive Structure and Congressional Refusal to Require
Pediatric Testing, 40 HARV. J. ON LEGIS. 133, 135–44 (2003) (analyzing reasons for the scarcity of pediatric clinical drug trials) (link). Since 1997, Congress has passed a series of measures to increase pediatric testing and labeling of drugs and devices. See, e.g., Food and Drug Administration
Modernization Act of 1997, Pub. L. No. 105-115, § 111, 111 Stat. 2296, 2305–09 (1997) (codified as
amended at 21 U.S.C. § 355a (2006) (link)) (link). These measures, however, have been voluntary, subject to waiver, and/or applied primarily to new drugs and devices, and some of the provisions are relatively new. Thus, it is not clear that they have significantly affected the frequency of off-label pediatric
uses.
16
See, e.g., U.S. Food and Drug Administration, Information for Consumers: Side Effects,
http://www.fda.gov/cder/info/consumer_safety.htm (last visited Apr. 2, 2009) (―All medicines have benefits and risks.‖) (link).
10
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the course of that treatment, the patient may sue and contend that the offlabel use was, in and of itself, a violation of the standard of care—that such
use was negligent.17 Undoubtedly, the patient will try to introduce the
drug‘s or device‘s label as evidence of the physician‘s alleged negligence.
One recent case reported that ―[v]irtually every court addressing [the]
question has concluded that the drug‘s labeling and PDR reference are relevant to the standard of care issue.‖18 According to that court, ―[s]everal jurisdictions, believing drug manufacturers to be uniquely knowledgeable
about the proper use of their products, have held that a drug‘s labeling or its
parallel PDR reference amounts to prima facie evidence of the standard of
care as far as the use of that drug is concerned.‖19 Nevertheless, ―a majority
of jurisdictions have determined that a prescription drug‘s labeling or parallel PDR reference is admissible to prove the standard of care, but only if the
plaintiff also introduces other expert testimony regarding the standard of
care.‖20
Both rationales for admitting drug and device labeling in off-label use
cases are incorrect. FDA-approved drug and device labeling is not relevant
evidence of the standard of medical care. And even if the labeling offered
some evidence of that standard, the risk of confusion, prejudice, and undue
waste of time would substantially outweigh that marginal relevance.
A. The FDA-Approved Label Is Not Relevant Evidence of the Standard of
Care
The plaintiff in a medical malpractice action must prove that the defendant physician failed to meet the standard of care, which in most jurisdictions is the level of skill and knowledge possessed by medical
professionals in the same or a similar community.21 Only evidence that is
relevant to establishing the standard of care should be admitted in the plaintiff‘s case. The FDA-approved label is not relevant evidence of the standard of care in an off-label use case for several reasons.

17
See Paul D. Rheingold & David B. Rheingold, Offense or Defense? Managing the Off-Label Use
Claim, 37 TRIAL, Mar. 2001, at 52, 52–55.
18
Richardson v. Miller, 44 S.W.3d 1, 15 (Tenn. Ct. App. 2000) (link). ―PDR‖ refers to the
PHYSICIANS‘ DESK REFERENCE, ―an encyclopedia of medications written and published annually and
provided to all practicing physicians.‖ Id. at 11. The PDR contains the same information drug manufacturers are required to include in their package insert labeling. Id.; see 21 C.F.R. § 201.100(c)–(d) (2008)
(link).
19
Richardson, 44 S.W.3d at 16 (citing cases).
20
Id. The treatment of drug and device labels in medical malpractice cases is also discussed in
Bird, supra note 7.
21
See, e.g., RESTATEMENT (SECOND) OF TORTS § 299A (1965) (―[O]ne who undertakes to render
services in the practice of a profession or trade is required to exercise the skill and knowledge normally
possessed by members of that profession or trade in good standing in similar communities.‖).
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1.

The FDA and Manufacturers Are Not Local Medical
Practice Standard Bearers
Drug and device labeling is a creature of federal regulatory law. The
FDA, the creature‘s master, has repeatedly said it does not regulate the
practice of medicine.22 Accordingly, the FDA has repeatedly confirmed that
the absence of a particular use from a drug‘s or device‘s approved label has
no legal effect on a physician‘s ability to put the drug or device to that use:






In a 1972 rulemaking proposal, the FDA stated that a
―physician may, as part of the practice of medicine,
lawfully prescribe a different dosage for his patient, or
may otherwise vary the conditions of use from those
approved in the package insert . . . .‖23 Thus, ―labeling
is not intended either to preclude the physician from
using his best judgment in the interest of the patient, or
to impose liability if he does not follow the package
insert.‖24
In a 1982 Drug Bulletin, the FDA stated that federal
law ―does not . . . limit the manner in which a physician
may use an approved drug. Once a product has been
approved for marketing, a physician may prescribe it
for uses or in treatment regimens or patient populations
that are not included in approved labeling.‖25
In a January 2009 industry guidance document, the
FDA stated that ―[o]nce a drug or medical device has
been approved or cleared by FDA, generally, healthcare professionals may lawfully use or prescribe that

22
See, e.g., More Information for Better Patient Care: Hearing on S. 1477 Before the S. Comm. on
Labor and Human Resources, 104th Cong. app. at 82 (1996) (statement of William B. Schultz, Deputy
Comm‘r for Policy, Food & Drug Admin.), available at http://www.fda.gov/ola/1996/s1447.html (arguing that ―[t]he legislative history of the Federal Food, Drug, and Cosmetic Act indicates that Congress
did not intend FDA to interfere with the practice of medicine,‖ and that ―once a drug is approved for
marketing, FDA does not generally regulate how, and for what uses, physicians prescribe that drug‖)
(link). The United States Supreme Court has reached the same conclusion. See Buckman Co. v. Plaintiffs‘ Legal Comm., 531 U.S. 341, 350 (2001) (stating that ―‗off-label‘ usage of medical devices (use of
a device for some other purpose than that for which it has been approved by the FDA) is an accepted and
necessary corollary of the FDA‘s mission to regulate in this area without directly interfering with the
practice of medicine‖) (link).
23
Legal Status of Approved Labeling for Prescription Drugs; Prescribing for Uses Unapproved by
the Food and Drug Administration, 37 Fed. Reg. 16,503, 16,503 (proposed Aug. 15, 1972) (link).
24
Id. at 16,504. Notwithstanding this clear statement that an off-label use is not unlawful, the FDA
also said in the same document that ―labeling, along with medical articles, tests, and expert opinion, may
constitute evidence of the proper practice of medicine . . . .‖ Id. (emphasis added).
25
12 FDA DRUG BULL., Apr. 1982, at 1, 5 (link).
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product for uses or treatment regimens that are not included in the product‘s approved labeling . . . .‖26
Congress, too, recognizes that off-label uses are not per se improper.
Federal law provides that ―[n]othing in [the Federal Food, Drug, and Cosmetic Act] shall be construed to limit or interfere with the authority of a
health care practitioner to prescribe or administer any legally marketed device to a patient for any condition or disease within a legitimate health care
practitioner-patient relationship.‖27 Also, Congress requires government insurance programs to pay for certain off-label uses.28
Unsurprisingly, federal29 and state courts30 are in accord. And, like
Congress, many state legislatures have at least tacitly approved certain offlabel uses by requiring insurance companies to cover them.31
These positions make sense because the FDA‘s information-gathering
role in the approval process is largely passive and static, relying generally
26
FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: GOOD REPRINT PRACTICES FOR THE
DISTRIBUTION OF MEDICAL JOURNAL ARTICLES AND MEDICAL OR SCIENTIFIC REFERENCE
PUBLICATIONS ON UNAPPROVED NEW USES OF APPROVED DRUGS AND APPROVED OR CLEARED
MEDICAL DEVICES 3 (2009) [hereinafter FDA, UNAPPROVED NEW USES REPRINT GUIDANCE], available
at http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0053-gdl.pdf (link). It is particularly
anomalous to admit the drug‘s labeling taken from the PDR, as some courts have done, because that
publication recognizes that the FDA-approved labeling it contains does not ―limit the manner in which a
physician may use an approved drug.‖ Foreword to PHYSICIANS‘ DESK REFERENCE (62d ed. 2008).
27
21 U.S.C. § 396 (2006) (link).
28
E.g., 42 U.S.C. § 1395x(t)(2)(A)–(B) (2006) (including off-label indications supported by specified medical publications in Medicare reimbursement program) (link).
29
See, e.g., Buckman Co. v. Plaintiffs‘ Legal Comm., 531 U.S. 341, 350 (2001); Ortho Pharm.
Corp. v. Cosprophar, Inc., 32 F.3d 690, 692 (2d Cir. 1994) (―[T]he FDA permits doctors to prescribe
drugs for ‗off-label‘ uses.‖) (link); Weaver v. Reagen, 886 F.2d 194, 198 (8th Cir. 1989) (―[T]he fact
that FDA has not approved labeling of a drug for a particular use does not necessarily bear on those uses
of the drug that are established within the medical and scientific community as medically appropriate.‖)
(link).
30
See, e.g., Sita v. Long Island Jewish-Hillside Med. Ctr., 803 N.Y.S.2d 112, 114 (N.Y. App. Div.
2005) (―Although marketing and promotion of the [treatment] system was not approved by the [FDA]
for treating the injured plaintiff‘s condition, this does not prevent a physician from using the system in
an ‗off-label‘ manner.‖) (link); State Bd. of Regents for the Healing Arts v. McDonagh, 123 S.W.3d
146, 150 (Mo. 2003) (―[N]on-FDA-approved, or ‗off-label,‘ use of medications by physicians is not
prohibited by the FDA and is generally accepted in the medical profession.‖) (link); Southard v. Temple
Univ. Hosp., 781 A.2d 101, 104 (Pa. 2001) (―The FDA does not preclude off-label use of medical devices. To the contrary, while the FDA regulates the marketing and labeling of medical devices, it does
not purport to interfere with the practice of medicine.‖).
31
E.g., ALA. CODE § 27-1-10.1 (LexisNexis 2007) (link); CAL. INS. CODE § 10123.195(a) (West
2005) (link); CONN. GEN. STAT. ANN. §§ 38a-492b(a) (link), 38a-518b(a) (link) (West 2007); FLA.
STAT. ANN. § 627.4239(2)(a) (West 2005) (link); 5 ILL. COMP. STAT. ANN. 375/6.4 (West 2005) (link);
MICH. COMP. LAWS ANN. §§ 500.3406e (link), 500.3616a (link) (West 2002); MO. ANN. STAT.
§§ 376.429(3) (link), 376.1361(11) (link) (West 2002 & Supp. 2009); N.H. REV. STAT. ANN. §§ 415:6-g
(link), 415:18-j (link) (LexisNexis 2009); N.J. STAT. ANN. § 26:1A-36.9 (West 2007) (link); OHIO REV.
CODE ANN. § 1751.66(A) (West Supp. 2008) (link); OKLA. STAT. ANN. tit. 63, §§ 1-2604, 1-2605 (West
2004) (link); R.I. GEN. LAWS § 27-55-2 (2008) (link); VA. CODE ANN. § 38.2-3407.5 (2007) (link).
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on only data that exists when approval is sought and for indications that the
manufacturer chooses to pursue.32 A physician, by contrast, has ―access to
new information on drugs through the medical literature, scientific meetings, postgraduate courses, and professional contacts with colleagues.‖33
Thus, ―[t]he package insert is not intended under the law to serve as a totally current repository of all such information.‖34
Drug and device manufacturers likewise are not attempting to define
the standard of care. They prepare labeling to get their products approved
and to market.35 Thus, courts have found that ―[t]he purposes behind the
[information a drug or device manufacturer provides about a product] render its contents ill-suited to serve as prima facie evidence of a standard of
care; they seek to cover a wide range of concerns not always directed at a
diagnosis and course of treatment.‖36
2.

There Are Many Reasons, Unrelated to Standards of
Care, Why a Use May Not Be Indicated “On Label”
The uses indicated in a drug‘s or device‘s FDA-approved labeling are
not evidence that another use is outside the standard of care because there
are compelling reasons why a widely accepted and demonstrably safe and
effective use for a drug or device may be omitted. For one, science advances more quickly than regulation.37 Physicians may discover the bene32

An FDA official has observed that, in some cases, the existing data regarding an off-label use is
sufficiently comprehensive that the use ―could be approved by FDA if the sponsor would simply compile the existing literature and submit it to us.‖ More Information for Better Patient Care: Hearing on S.
1477 Before the S. Comm. on Labor & Human Res., 104th Cong. app. at 88 (1996) (statement of William B. Schultz, Deputy Comm‘r for Policy, Food & Drug Admin.), available at
http://www.fda.gov/ola/1996/s1447.html (link).
33
Labeling for Prescription Drugs Used in Man: Proposed Format of Prescription-Drug Advertisements, 40 Fed. Reg. 15,392, 15,394 (proposed Apr. 7, 1975).
34
Id. Courts have also recognized the limitation. See, e.g., United States v. Evers, 453 F. Supp.
1141, 1149 (M.D. Ala. 1978) (―It is well-recognized that a package insert may not contain the most upto-date information about a drug . . . .‖) (link). After the FDA approves a drug or device for an indicated
use, it continues to monitor adverse events and may withdraw its approval if it determines that the drug
or device is not safe for that use. See, e.g., 21 C.F.R. §§ 314.80 (link), 314.150 (link) (2008). The FDA
will not, however, act to approve a new use unless the manufacturer submits the appropriate supporting
information. See supra note 32 and accompanying text.
35
E.g., Arnold v. Lee, No. 05-0651, 2006 WL 1410161, at *4 (Iowa Ct. App. May 24, 2006) (stating that ―the manufacturer has its own reasons for the information contained in the package inserts,‖
which ―are not limited to altruism or the education of the medical community‖). See also Bird, supra
note 7, at 416 (noting that the American Medical Association ―has repeatedly alleged that inserts are an
inadequate standard for medical practice, pointing to the inconsistent purposes served by the documentadvertising for the manufacturer, regulation by the government, and information for the doctor‖).
36
Spensieri v. Lasky, 723 N.E.2d 544, 548 (N.Y. 1999) (internal citations omitted) (link).
37
E.g., Sidney A. Shapiro, Limiting Physician Freedom to Prescribe a Drug for Any Purpose: The
Need for FDA Regulation, 73 NW. U. L. REV. 801, 811 (1978) (observing that off-label uses ―are unlikely ever to be eliminated since there is an unavoidable lag between the time a new use for a drug is discovered and the time that use is approved by the FDA‖). Indeed, a manufacturer may not even start the
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fits of an off-label use and share those benefits with others, through journals, presentations, and professional associations, long before the FDA approves the use.38
Even if science and regulation advanced at the same rate, however,
there are several reasons why much standard of care medicine would still
not be reflected in drug or device labeling.39 First, ―[b]ecause of the time
and expense of obtaining FDA approval of new uses for an already approved drug, drug manufacturers frequently do not voluntarily request FDA
approval for a new use unless the change in the labeling will pay for itself
in increased profits.‖40 Self-funding label changes are particularly unlikely
when the drug‘s or device‘s patent is nearing expiration (thus exposing the
drug or device to generic competition)41 and when the market for the offlabel use is small.42
Second, drug and device manufacturers have limited research and development dollars, and they may decide those dollars are better spent pursuing groundbreaking new therapies than seeking approval for new uses of
products already being sold.43
Third, limited resources may also make it difficult for manufacturers to
find researchers willing to perform the clinical trials necessary to obtain
FDA approval for the new use. When the off-label use to be investigated is
already widely accepted, researchers may find the investigation to be ―at
least uninteresting, if not a waste of time.‖44
Fourth, when the off-label use is already widely accepted as beneficial,
the availability of researchers may also be limited by ethical constraints:
―The conflict between the patient‘s therapeutic needs and the needs of the
experimental trial [such as supplying placebos to the control group of afflicted subjects] poses ethical problems which may deter a physician from
acting as an investigator.‖45
testing required to support FDA approval for a new use until after that use becomes the medically accepted standard. Id.
38
See 12 FDA DRUG BULL., supra note 25, at 5.
39
See Stuart L. Nightingale, Off-Label Use of Prescription Drugs, 68 AM. FAM. PHYSICIAN 425,
425–26 (2003) (link).
40
Richardson v. Miller, 44 S.W.3d 1, 12 (Tenn. Ct. App. 2000). The General Accounting Office
similarly observed that, when an off-label use is proven effective, ―the manufacturer can ask the FDA to
make a formal change in the label that would reflect the expanded benefits of the drug. However, representatives from the pharmaceutical industry characterize this process as cumbersome, time-consuming,
and expensive compared to the payoff for a company.‖ GAO REPORT, supra note 13, at 11 n.2.
41
See GAO REPORT, supra note 13, at 11 n.2.
42
See, e.g., Beck & Azari, supra note 1, at 80 n.80 (observing that ―[m]ost diseases afflicting fewer
than 200,000 Americans‖ do not have FDA-labeled treatments).
43
Noah, supra note 11, at 145.
44
David A. Kessler, Regulating the Prescribing of Human Drugs for Nonapproved Uses Under the
Food, Drug, and Cosmetic Act, 15 HARV. J. ON LEGIS. 693, 730 (1978).
45
Id.; see Jennifer A. Henderson & John J. Smith, Realizing the Potential for Biomarkers in Imaging: Background and Legal Basis, 60 FOOD & DRUG L.J. 511, 515–16 (2005) (link).
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Fifth, when the off-label use is already the standard of care for a particular disease or condition, it may be difficult to find a traditional control
group, because most people afflicted with the disease or condition are already receiving the off-label treatment that is to be studied.46
Sixth, if a manufacturer seeks approval for a new use, the FDA may
choose to revisit the entire label.47 If the original label resulted from compromise between the manufacturer and the FDA, the manufacturer may
wish not to reopen these negotiations.48
Congress‘s efforts to induce manufacturers to seek FDA approval for
off-label uses have not entirely cured these disincentives. Although manufacturers are not permitted to market a drug for off-label use, the 1997 Food
and Drug Administration Modernization Act allowed manufacturers to disseminate certain scientific literature about an off-label use if the manufacturer had submitted, or certified that it would submit, a supplemental
application seeking FDA approval for the use.49 The statute permitted manufacturers to disseminate information without submitting, or promising to
submit, a supplemental application, however, when it would be ―economically prohibitive . . . to conduct the studies necessary to submit a supplemental application for the [off-label] use.‖50 And, of course, manufacturers
willing to rely on the medical community to spread the word about a particular off-label use would not subject themselves to this rule. In any case,
this provision and its implementing regulations expired in 2006.51 The FDA
recently issued an industry guidance statement on the topic, which suggests
that manufacturers may continue to disseminate certain types of literature
about off-label uses, but without requiring manufacturers to submit, or
promise to submit, a supplemental application for FDA approval of those
uses.52
Thus, there are many reasons—unrelated to the standard of care—why
certain uses of a drug or device would not be indicated in the FDAapproved labeling.

46

Henderson & Smith, supra note 45, at 515–16.
Shapiro, supra note 37, at 812 n.77.
48
Id.; see Kessler, supra note 44, at 723–24.
49
See Pub. L. No. 105-115, § 401(a), 111 Stat. 2296, 2356–63 (1997) (codified as amended at 21
U.S.C. §§ 360aaa–360aaa-6) (expired 2006) (link).
50
21 C.F.R. § 99.205(b) (2008) (link). To qualify for this exemption, the manufacturer must explain why the data in the disseminated study are not sufficient to support the supplemental application
and present evidence that the cost of the studies necessary to support the supplemental application exceeds the expected net revenues from the off-label use. Id. § 99.205(b)(1)(i)–(ii).
51
Food and Drug Administration Modernization Act, § 401(e), 111 Stat. at 2364 (link); FDA,
UNAPPROVED NEW USES REPRINT GUIDANCE, supra note 26, at 2.
52
FDA, UNAPPROVED NEW USES REPRINT GUIDANCE, supra note 26, at 2–6.
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3. Off-Label Use May Actually Be the Standard of Care
An FDA-approved label should not be admissible as evidence of the
standard of care because the FDA, as well as leading medical authorities
and courts, have recognized that an off-label use may well be the safest,
most effective, state-of-the-art treatment. Indeed, the off-label use may itself constitute the standard of care. For example:








The FDA, in an industry guidance document, which
represents the FDA‘s ―current thinking,‖ observes that
―off-label uses or treatment regimens . . . may even
constitute a medically recognized standard of care.‖53
The General Accounting Office‘s Director of Health
Services Quality and Public Health Issues testified to a
congressional subcommittee that ―a drug given offlabel may have been proven to be safer and more beneficial than any drug labeled for that disease.‖54
Courts have found that ―[b]ecause the pace of medical
discovery runs ahead of the FDA‘s regulatory machinery, the off-label use of some drugs is frequently considered to be ‗state-of-the-art‘ treatment.‖ Indeed, ―[i]n
some circumstances, an off-label use of a particular
drug or device may even define the standard of care.‖55
According to the vice president of the American Medical Association, ―‗[i]n some cases, if you didn‘t use the
drug in the off-label way you‘d be guilty of malpractice.‘‖56

Neither the FDA nor manufacturers intend to set the standard of care
for medical malpractice purposes in drug and device labeling. There are
many reasons why uses that conform to the standard of care may be omitted
from an FDA-approved label. An FDA-approved label‘s silence as to a particular use is therefore evidence of nothing in an off-label medical malpractice case.

53

Id. at 3.
Off-Label Drug Use and FDA Review of Supplemental Drug Applications: Hearing Before the
Subcomm. on Human Resources and Intergovernmental Relations of the H. Comm. on Government
Reform and Oversight, 104th Cong. 12 (1996) (statement of Sarah F. Jaggar, Director of Health Services
Quality and Public Health Issues, Health, Education, and Human Services Division, Gen. Accounting
Office) (link).
55
E.g., Richardson v. Miller, 44 S.W.3d 1, 13 n.11 (Tenn. Ct. App. 2000).
56
Fran Kritz, FDA Seeks to Add Drugs’ New Uses to Labels, WASH. POST, Mar. 29, 1994, at Z11.
54
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B. Admitting Drug and Device Labels Poses a Substantial Risk of
Prejudice and Confusion
Some courts have admitted FDA-approved drug and device labels as
―some evidence‖ of the standard of care.57 For all the reasons explained
above, those courts decided wrongly. But even if FDA-approved labels had
some evidentiary value in an off-label use case, that value would be outweighed by the significant risk of prejudice, confusion, and time-wasting
that its admission would cause.58
Indeed, just the terminology associated with off-label use poses the risk
of prejudice and confusion. Uses of drugs and devices not indicated on the
drug‘s or device‘s labeling can be called ―unapproved,‖ ―unlabeled,‖ ―offlabel,‖ or ―extra-label.‖59 As the FDA itself recognized, ―[t]he term ‗unapproved uses‘ is, to some extent, misleading. It includes a variety of situations ranging from unstudied to thoroughly investigated drug uses.‖60
Consumer survey data confirm these risks. According to a 2006 Wall
Street Journal/Harris Interactive Health-Care Poll, fifty percent of adults
in the United States (out of 3,018 surveyed) believe that, once a drug is approved by the FDA, a physician may prescribe the drug for only the FDAapproved uses; another twenty-five percent were unsure.61 A trial laden
with references to ―unapproved‖ uses would also inappropriately pander to
jurors‘ views that off-label uses should not be permitted. The same survey
found that nearly half of respondents believe that physicians should not be
allowed to prescribe a drug to treat diseases other than the diseases indicated in the FDA-approved labeling for that drug.62 More respondents disagreed than agreed that ―[d]octors should be allowed to decide which
prescription drug treatments to use with their patients regardless of what
diseases they have or have not been approved for by the FDA.‖63 And sixty-two percent of respondents agreed that ―[p]rescription drug use for unapproved medical conditions should be prohibited except as part of the
clinical research trial.‖64

57

See, e.g., supra note 20 and accompanying text.
See FED. R. EVID. 403 (link).
59
Citizen Petition Regarding the Food and Drug Administration‘s Policy on Promotion of Unapproved Uses of Approved Drugs and Devices; Request for Comments, 59 Fed. Reg. 59,820, 59,820
(Nov. 18, 1994) (link).
60
12 FDA DRUG BULL., supra note 25, at 5.
61
Harris Interactive News Room, U.S. Adults Ambivalent About the Risks and Benefits of OffLabel
Prescription
Drug
Use
(Dec.
7,
2006),
http://www.harrisinteractive.com/news/allnewsbydate.asp?NewsID=1126 (link).
62
Id.
63
Id.
64
Id.
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These 2006 results confirm the results of a similar survey conducted in
2004.65 Together, these surveys demonstrate that public misconception and
distrust about off-label use is common and deep-seated.
At least one court has, without the benefit of this type of survey data,
concluded that the risk of confusion and prejudice could be adequately addressed through cross-examination and jury instructions.66 But if either of
those were a panacea, then Federal Rule of Evidence 403 and its state law
analogues, which exclude evidence likely to confuse and more prejudicial
than probative, would not be necessary. And the Harris Poll results demonstrate the sort of ―widely held prejudice‖67 that courts have relied on to exclude evidence under those rules.68
Evidence that a particular use is off-label should also be excluded to
avoid wasting time.69 Consider, for example, the case in which the plaintiff
relies exclusively on the off-label nature of the use as proof of malpractice.
If the physician‘s expert witness will testify that the off-label use was, in
fact, the state-of-the-art treatment, and the judge will instruct the jury that
an off-label use is not negligence per se, then the label would come in, only
to be refuted by evidence that the physician and court hope will erase the
label‘s effect on the jurors. This wastes time and may breed confusion.
Even if the plaintiff offered expert testimony in addition to the product
label to establish the standard of care, admitting the label would waste time.
In a field such as oncology, for example,70 the plaintiff would offer the label
and the defense expert would testify that most treatments are off-label and
so the uses indicated on the label are far removed from the standard of care.
The physician in that type of case may or may not have committed malpractice, but admitting the label consumes time without giving the jury useful
information.
CONCLUSION
Drug and device labels reflect competing regulatory and commercial
interests. Because they are frozen in time, they may not reflect advances in
65
The 2004 survey asked the same questions as the 2006 survey. Harris Interactive News Room,
Many People Think that Drugs Should Only Be Prescribed Per FDA-Approved Use, Not for Off-Label
Use (Jun. 9, 2004), http://www.harrisi.org/news/allnewsbydate.asp?NewsID=808 (link). The chairman
of the Harris Poll observed that these results indicated ―‗massive public ignorance of ―off-label prescribing,‖‘‖ and that, notwithstanding the ―‗several strong arguments in favor of off-label prescribing, . . .
these data suggest that it is a potentially risky issue for both physicians and the pharmaceutical industry‘
. . . .‖ Id.
66
Richardson v. Miller, 44 S.W.3d 1, 22 (Tenn. Ct. App. 2000).
67
United States v. Kott, No. 3:07-cr-00056 JWS, 2007 WL 2461930, at *2 (D. Alaska Aug. 29,
2007).
68
See, e.g., id. (excluding evidence that legislator had filed previous false per diem claims because
it ―would tend to support the widely held prejudice that many legislators are entirely corrupt‖).
69
See FED. R. EVID. 403.
70
See supra note 13 and accompanying text.
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the medical state-of-the-art. The FDA has repeatedly recognized that offlabel uses are generally allowed and may be the standard of care. Thus, the
absence of a use from an FDA-approved label proves nothing about the
standard of care or a physician‘s deviation from (or adherence to) that standard when he or she employs that off-label use. Allowing plaintiffs in offlabel medical malpractice cases to introduce evidence that the physician‘s
use was ―off-label,‖ ―unapproved,‖ or ―unauthorized‖ unfairly appeals to
commonly held misconceptions about the effect of FDA approval. Defendants in these types of cases must know and use all the arguments available
to oppose the admission of this off-label evidence, and courts must be made
more aware of this evidence‘s prejudicial dangers.
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